These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 38755613)

  • 1. A humanized trivalent Nectin-4-targeting nanobody drug conjugate displays potent antitumor activity in gastric cancer.
    Wu Y; Zhu M; Sun B; Chen Y; Huang Y; Gai J; Li G; Li Y; Wan Y; Ma L
    J Nanobiotechnology; 2024 May; 22(1):256. PubMed ID: 38755613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Homogeneous tumor targeting with a single dose of HER2-targeted albumin-binding domain-fused nanobody-drug conjugates results in long-lasting tumor remission in mice.
    Xenaki KT; Dorrestijn B; Muns JA; Adamzek K; Doulkeridou S; Houthoff H; Oliveira S; van Bergen En Henegouwen PM
    Theranostics; 2021; 11(11):5525-5538. PubMed ID: 33859761
    [No Abstract]   [Full Text] [Related]  

  • 3. Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models.
    Challita-Eid PM; Satpayev D; Yang P; An Z; Morrison K; Shostak Y; Raitano A; Nadell R; Liu W; Lortie DR; Capo L; Verlinsky A; Leavitt M; Malik F; Aviña H; Guevara CI; Dinh N; Karki S; Anand BS; Pereira DS; Joseph IB; Doñate F; Morrison K; Stover DR
    Cancer Res; 2016 May; 76(10):3003-13. PubMed ID: 27013195
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of Site-Specifically Conjugated Monomethyl Auristatin E- and Duocarmycin-Based Anti-PSMA Antibody-Drug Conjugates for Treatment of PSMA-Expressing Tumors.
    Lütje S; Gerrits D; Molkenboer-Kuenen JD; Herrmann K; Fracasso G; Colombatti M; Boerman OC; Heskamp S
    J Nucl Med; 2018 Mar; 59(3):494-501. PubMed ID: 29146698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A potential strategy for bladder cancer treatment: inhibiting autophagy to enhance antitumor effects of Nectin-4-MMAE.
    Wang Y; Nan Y; Ma C; Lu X; Wang Q; Huang X; Xue W; Fan J; Ju D; Ye D; Zhang X
    Cell Death Dis; 2024 Apr; 15(4):293. PubMed ID: 38664366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E-based Antibody-Drug Conjugate for Treatment of Nectin-4-expressing Cancers.
    Zhou W; Fang P; Yu D; Ren H; You M; Yin L; Mei F; Zhu H; Wang Z; Xu H; Cao Y; Sun X; Xu X; Bi J; Wang J; Ma L; Wang X; Chen L; Zhang Y; Cen X; Zhu X; Lou L; Liu D; Tan X; Yang J; Meng T; Shen J
    Mol Cancer Ther; 2023 Aug; 22(8):913-925. PubMed ID: 37196158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HER2-targeted antibody drug conjugates for ovarian cancer therapy.
    Jiang J; Dong L; Wang L; Wang L; Zhang J; Chen F; Zhang X; Huang M; Li S; Ma W; Xu Q; Huang C; Fang J; Wang C
    Eur J Pharm Sci; 2016 Oct; 93():274-86. PubMed ID: 27509865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An EGFR-targeting antibody-drug conjugate LR004-VC-MMAE: potential in esophageal squamous cell carcinoma and other malignancies.
    Hu XY; Wang R; Jin J; Liu XJ; Cui AL; Sun LQ; Li YP; Li Y; Wang YC; Zhen YS; Miao QF; Li ZR
    Mol Oncol; 2019 Feb; 13(2):246-263. PubMed ID: 30372581
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An antibody-drug conjugate targeting a GSTA glycosite-signature epitope of MUC1 expressed by non-small cell lung cancer.
    Pan D; Tang Y; Tong J; Xie C; Chen J; Feng C; Hwu P; Huang W; Zhou D
    Cancer Med; 2020 Dec; 9(24):9529-9540. PubMed ID: 33084221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel human single-domain antibody-drug conjugate targeting CEACAM5 exhibits potent in vitro and in vivo antitumor activity.
    Zhu XY; Li QX; Kong Y; Huang KK; Wang G; Wang YJ; Lu J; Hua GQ; Wu YL; Ying TL
    Acta Pharmacol Sin; 2024 Mar; 45(3):609-618. PubMed ID: 38030799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis, characterization, and targeted chemotherapy of SCT200-linker-monomethyl auristatin E conjugates.
    Hu X; Jiang H; Bai W; Liu X; Miao Q; Wang L; Jin J; Cui A; Liu R; Li Z
    Eur J Med Chem; 2021 Apr; 216():113297. PubMed ID: 33677351
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody-drug conjugates with HER2-targeting antibodies from synthetic antibody libraries are highly potent against HER2-positive human gastric tumor in xenograft models.
    Kuo WY; Hsu HJ; Wu CY; Chen HS; Chou YC; Tsou YL; Peng HP; Jian JW; Yu CM; Chiu YK; Chen IC; Tung CP; Hsiao M; Lin CL; Wang YA; Wang AH; Yang AS
    MAbs; 2019 Jan; 11(1):153-165. PubMed ID: 30365359
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TROP2-directed nanobody-drug conjugate elicited potent antitumor effect in pancreatic cancer.
    Xu C; Zhu M; Wang Q; Cui J; Huang Y; Huang X; Huang J; Gai J; Li G; Qiao P; Zeng X; Ju D; Wan Y; Zhang X
    J Nanobiotechnology; 2023 Nov; 21(1):410. PubMed ID: 37932752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nectin-4: a new prognostic biomarker for efficient therapeutic targeting of primary and metastatic triple-negative breast cancer.
    M-Rabet M; Cabaud O; Josselin E; Finetti P; Castellano R; Farina A; Agavnian-Couquiaud E; Saviane G; Collette Y; Viens P; Gonçalves A; Ginestier C; Charafe-Jauffret E; Birnbaum D; Olive D; Bertucci F; Lopez M
    Ann Oncol; 2017 Apr; 28(4):769-776. PubMed ID: 27998973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An anti-HER2 antibody conjugated with monomethyl auristatin E is highly effective in HER2-positive human gastric cancer.
    Li H; Yu C; Jiang J; Huang C; Yao X; Xu Q; Yu F; Lou L; Fang J
    Cancer Biol Ther; 2016 Apr; 17(4):346-54. PubMed ID: 26853765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of BT8009: A Nectin-4 Targeting Bicycle Toxin Conjugate for the Treatment of Cancer.
    Mudd GE; Scott H; Chen L; van Rietschoten K; Ivanova-Berndt G; Dzionek K; Brown A; Watcham S; White L; Park PU; Jeffrey P; Rigby M; Beswick P
    J Med Chem; 2022 Nov; 65(21):14337-14347. PubMed ID: 36204777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trastuzumab-monomethyl auristatin E conjugate exhibits potent cytotoxic activity in vitro against HER2-positive human breast cancer.
    Abdollahpour-Alitappeh M; Lotfinia M; Bagheri N; Sineh Sepehr K; Habibi-Anbouhi M; Kobarfard F; Balalaie S; Foroumadi A; Abbaszadeh-Goudarzi G; Abbaszadeh-Goudarzi K; Abolhassani M
    J Cell Physiol; 2019 Mar; 234(3):2693-2704. PubMed ID: 30246298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nanoparticle conjugates of a highly potent toxin enhance safety and circumvent platinum resistance in ovarian cancer.
    Qi R; Wang Y; Bruno PM; Xiao H; Yu Y; Li T; Lauffer S; Wei W; Chen Q; Kang X; Song H; Yang X; Huang X; Detappe A; Matulonis U; Pepin D; Hemann MT; Birrer MJ; Ghoroghchian PP
    Nat Commun; 2017 Dec; 8(1):2166. PubMed ID: 29255160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic efficacy, pharmacokinetic profiles, and toxicological activities of humanized antibody-drug conjugate Zt/g4-MMAE targeting RON receptor tyrosine kinase for cancer therapy.
    Yao HP; Feng L; Suthe SR; Chen LH; Weng TH; Hu CY; Jun ES; Wu ZG; Wang WL; Kim SC; Tong XM; Wang MH
    J Immunother Cancer; 2019 Mar; 7(1):75. PubMed ID: 30871619
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel humanized anti-HER2 antibody conjugated with MMAE exerts potent anti-tumor activity.
    Yao X; Jiang J; Wang X; Huang C; Li D; Xie K; Xu Q; Li H; Li Z; Lou L; Fang J
    Breast Cancer Res Treat; 2015 Aug; 153(1):123-33. PubMed ID: 26253944
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.